Inari's Five Levers of Growth According to the CEO

According to the CDC, up to 600,000 Americans are diagnosed with deep vein thrombosis (DVT) or pulmonary embolisms (PE) each year. These blood clots kill between 60,000 and 100,000 people annually, often within months of a diagnosis. Inari Medical (NASDAQ: NARI), which came public last May, developed interventional products to treat these clots. Rather than risky, expensive, often ineffective drugs, the company's ClotTriever and FlowTriever devices are catching on with physicians.

Sales, and the stock, climbed rapidly last year. CEO William Hoffman believes the growth is just beginning. Through its short history as a public company, he has consistently pointed to five areas that will be critical to maintaining the trajectory. Investors can look to these each quarter and evaluate whether Inari's performance is on track. Let's look at how it's going so far.

Image source: Getty Images.

Source Fool.com